NAD 299Cat No.
3282
|
Price and Availability |
|
Chemical Name: (3R)-3-(Dicyclobutylamino)-8-fluoro-3,4-dihydro-2H-1-be nzopyran-5-carboxamide hydrochloride |
|
Biological Activity
Selective, high affinity 5-HT1A receptor antagonist (Ki = 0.6 nM in vitro). Enhances the action of selective 5-HT reuptake inhibitors and reverses citalopram-induced inhibition of serotonergic cell firing.Licensing Information
Sold for research purposes under agreement from AstraZenecaTechnical Data
M.Wt:The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis and MSDS.
Resources
Certificate of Analysis / MSDS
References
Johansson et al (1997) The pharmacological characterization of a novel selective 5-hydroxytryptamine-1a receptor antagonist, NAD-299. J.Pharamacol.Exp.Ther. 283 216. Larsson et al (1998) Differential regional antagonism of 8-OH-DPAT-induced decrease in serotonin synthesis by two 5-HT1a receptor antagonists. Eur.J.Pharmacol. 346 209. Arborelius et al (1999) The 5-HT1a receptor antagonist robalzotan completely reverses citalopram-induced inhibition of serotonergic cell firing. Eur.J.Pharmacol. 382 133.If you know of a useful citation for this product please let us know.
Keywords: NAD 299, AstraZeneca, 5-HT1A, serotonin, 5-HT, receptor, antagonists
Buy Now / Print Quote
Find multiple products by catalog number
Print Quote Facility
Order via your purchasing department
It's now even easier to place orders via your purchasing department.
Simply add a product to your cart & click on the "Print Quote" button.
GPCRs and Signalling Networks
Written by M.J. Marinissen
'G-Protein-coupled Receptors and Signalling Networks' summarizes the intricate network of intracellular signalling pathways involved in GPCR function.
Neurobiology of Parkinson's Disease
Written by A. Schapira
'Neurobiology and Therapeutics of Parkinson's Disease' highlights the neurobiology of Parkinson's disease and highlights current and novel therapeutic interventions.
7-TM Receptor Signalling
Written by T. Kenakin et al
'Seven Transmembrane Receptor Signalling' highlights the multiple behaviors of 7-TMs including G-protein-dependent and -independent signaling as well as the concept of collateral efficacy
Antidepressants - Current and Future Targets
Written by P. Skolnich et al
'Antidepressants - Current and Future Targets' provides an overview of the current and future targets for the treatment of major depressive disorder.
New Products in this Area
Selective, high affinity 5-HT1A receptor antagonist
Donitriptan hydrochloride5-HT1B/1D agonist
CP 135807Selective 5-HT1D agonist
Eletriptan hydrobromideOrally active, selective 5-HT1B/1D agonist
Careers at Tocris
Tocris Bioscience currently has opportunities for a Chemistry Technician.
If you would like to be considered for any positions not currently advertised, we welcome your speculative application.
